Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01631656 · ClinicalTrials.gov registry record · NA
Combination Gel and Vascular ND in Mild to Moderate Rosacea
A NA study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT01631656 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 10 participants.
The verdict
NCT01631656, a NA study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a single center, open-label, split-face, prospective study of ten to fifteen subjects seeking vascular laser therapy for the treatment of mild to moderate rosacea. Subjects will be screened for eligibility for vascular laser therapy outside of the confines of this protocol. Once approved for laser, subjects will be screened for study enrollment and topical treatment of their rosacea at the Screening/Baseline visit. All subjects will receive Finacea 15% gel and will be instructed to apply the study drug to one half of the face, twice daily. Drug application will be modified just prior to and after the subjects' laser treatment to reduce irritation. Subjects will undergo Vascular Nd:Yag laser therapy to involved areas over the whole face two weeks after initiating Finacea treatment. Subjects will continue to use Finacea gel to one half of the face for the duration of the study.
Interventions
- DRUG Azelaic acid
- DEVICE Nd:Yag laser
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01631656
The ClinicalTrials.gov registry entry for NCT01631656 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azelaic acid is the first listed.
NCT01631656 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01631656 about?
NCT01631656 is a clinical study titled "Combination Gel and Vascular ND in Mild to Moderate Rosacea". This is a single center, open-label, split-face, prospective study of ten to fifteen subjects seeking vascular laser therapy for the treatment of mild to moderate rosacea. Subjects will be screened for eligibility for vascular laser therapy outside of the confines of this protocol. Once approved for...
What is the current status of trial NCT01631656?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2010-07. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01631656?
The interventions under investigation include: Azelaic acid (DRUG), Nd:Yag laser (DEVICE).
Who is sponsoring clinical trial NCT01631656?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.